Outset Medical, Inc. insider trading
Every open-market purchase and sale by Outset Medical, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Outset Medical, Inc.’s insiders pay?
From December 9, 2020 to October 5, 2026, 14 insiders reported 4 open-market purchases and 85 sales not made under a pre-set plan in Outset Medical, Inc. Twelve months after each purchase was reported, the shares were −57.6% against the S&P 500 on average (median −41.9%), over 3 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −86.9% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 12, 2021 into $1,692 by November 2, 2026, −28.9% a year. It held shares 38% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $12,928 (+5.1% a year), and held throughout $18,229 (+12.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Trigg Leslie | Chair and CEO | 0 | — | — | 23 | −88.7% (12) | August 18, 2026 |
| Ahmed Nabeel | Chief Financial Officer | 1 | −41.4% (1) | 0% | 13 | −83.0% (9) | May 16, 2025 |
| Brottem John L. | General Counsel | 0 | — | — | 14 | −106.6% (7) | August 18, 2026 |
| Williamson Steven S. | Chief Commercial Officer | 0 | — | — | 9 | −91.8% (9) | January 8, 2024 |
| Racine Jean-Olivier | Chief Technology Officer | 0 | — | — | 7 | −90.8% (6) | May 10, 2024 |
| Porter Stacey L. | Chief People Officer | 0 | — | — | 5 | −96.2% (5) | January 8, 2024 |
| Nash Marc | EVP Operations R&D & Service | 0 | — | — | 4 | — | January 21, 2026 |
| Vazquez Martin | Chief Operating Officer | 0 | — | — | 3 | −88.3% (3) | February 16, 2023 |
| Warburg Pincus LLC and related entities | 10% owner | 0 | — | — | 3 | −36.1% (3) | April 15, 2021 |
| Gaeta Renee | Chief Financial Officer | 0 | — | — | 2 | — | August 18, 2026 |
| Hinrichs James F. | Director | 2 | −65.7% (2) | 0% | 0 | — | November 22, 2022 |
| Leonard Braden Michael | 10% owner | 1 | — | — | 0 | — | October 5, 2026 |
| Warburg Pincus Private Equity X, L.P. | Director | 0 | — | — | 1 | −42.9% (1) | January 7, 2021 |
| Warburg Pincus X, L.P. | Director | 0 | — | — | 1 | −40.5% (1) | December 9, 2020 |
When several insiders traded Outset Medical, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Outset Medical, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −5.1% against the index. After 5 selling crowds, −2.7%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| January 30, 2026 | 3 selling | −17.4% | −10.5% | not yet |
| November 30, 2022 | 3 selling | +11.5% | 0.0% | −87.4% |
| July 29, 2022 | 3 selling | +7.3% | +81.7% | +19.2% |
| March 31, 2022 | 5 selling | −50.3% | −44.7% | −51.1% |
| August 31, 2021 | 2 buying | −5.0% | −5.1% | −51.7% |
| January 29, 2021 | 3 selling | +2.5% | −40.2% | −54.0% |